Endothelial Function in Obstructive Sleep Apnea

Progress in Cardiovascular Diseases

Volumn 51, Issue 5, 2009, Pages 351-362

  Atkeson, Amy ^a,b   Yeh, Susie Yim ^a,b   Malhotra, Atul ^a,b   Jelic, Sanja ^a,b  

^a Allergy   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; ALLOPURINOL; ANGIOTENSIN II; ANTIOXIDANT; ASCORBIC ACID; C REACTIVE PROTEIN; CD15 ANTIGEN; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ERYTHROPOIETIN; GLYCOPROTEIN P 15095; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTANOID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADENOTONSILLECTOMY; AGING; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BIOAVAILABILITY; BLOOD CLOTTING; BLOOD FLOW; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DEVICE THERAPY; DISEASE ACTIVITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOXIA; LEUKOCYTE; OBESITY; OXIDATIVE STRESS; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; PROTEIN BLOOD LEVEL; REOXYGENATION; REVIEW; SLEEP APNEA SYNDROME; SPLINT; STROKE; THROMBOCYTE ACTIVATION; TISSUE REPAIR; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; UVULOPALATOPHARYNGOPLASTY; VASCULITIS; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANOXIA; ANTIOXIDANTS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CONTINUOUS POSITIVE AIRWAY PRESSURE; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MANDIBULAR ADVANCEMENT; NITRIC OXIDE; OXIDATIVE STRESS; REGENERATION; SLEEP APNEA, OBSTRUCTIVE; SLEEP DEPRIVATION;

EID: 60649118976     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2008.08.002     Document Type: Review

References (121)

1. Young T., Palta M., Dempsey J., et al. The occurrence of sleep disordered breathing among middle-aged adults. N Engl J Med 328 (1993) 1230-1235
2. Guilleminault C., Tilkian A., and Dement W.C. The sleep apnea syndromes. Annu Rev Med 27 (1976) 465-484
3. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342 (2000) 1378-1384
4. Peker Y., Kraiczi H., Hedner J., et al. An independent association between obstructive sleep apnea and coronary artery disease. Eur Respir J 13 (1999) 179-184
5. Yaggi H.K., Concato J., Kernan W.N., et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353 (2005) 2034-2041
6. Aird W.C. Phenotypic heterogeneity of the endothelium: representative vascular beds. Circ Res 100 (2007) 174-190
7. Huang P.L. Unraveling the links between diabetes, obesity, and cardiovascular disease. Circ Res 96 (2005) 1129-1131
8. Ohga E., Nagase T., Tomita T., et al. Increased levels of circulating ICAM-1, VCAM-1, and l-selectin in obstructive sleep apnea syndrome. J Appl Physiol 87 (1999) 10-14
9. Dyugovskaya L., Lavie P., and Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 165 (2002) 934-939
10. Dyugovskaya L., Lavie P., and Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 1051 (2005) 340-350
11. Schulz R., Mahmoudi S., Hattar K., et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Am J Respir Crit Care Med 162 (2000) 566-570
12. Minoguchi K., Yokoe T., Tazaki T., et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 172 (2005) 625-630
13. Jelic S., Padeletti M., Higgins C., et al. Inflammation, oxidative stress and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 117 (2008) 2270-2278
14. Kato M., Roberts-Thomson P., Phillips B.G., et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 102 (2000) 2607-2610
15. Carlson J., Rangemark C., and Hedner J. Attenuated endothelium-dependent vascular relaxation in patients with sleep apnea. J Hypertens 14 (1996) 577-584
16. Ip M.S., Tse H.F., Lam B., et al. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med 169 (2004) 348-353
17. Marin J.M., Carrizo S.J., Vicente E., et al. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365 (2005) 1046-1053
18. Corretti M., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 39 (2000) 257-265
19. Pohl U., Holtz J., Busse R., et al. Crucial role of the endothelium in the vasodilator response to flow in vivo. Hypertension 8 (1985) 37-44
20. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (1995) 1314-1319
21. Sun D., Huang A., Smith C.J., et al. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilatation in eNOS-knockout mice. Circ Res 85 (1999) 288-293
22. Nieto F.J., Herrington D.M., Redline S., et al. Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med 169 (2004) 354-360
23. Ip M.S., Lam B., Chan L.Y., et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 162 (2000) 2166-2171
24. Schulz R., Schmidt D., Blum A., et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnea: response to CPAP therapy. Thorax 55 (2000) 1046-1051
25. Ohike Y., Kozaki K., Iijima K., et al. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure-possible involvement of nitric oxide and asymmetric NG,NG-dimethylarginine. Circ J 69 (2005) 221-226
26. Møller D.S., Lind P., Strunge B., et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 16 (2003) 274-280
27. Gjørup P.H., Sadauskiene L., Wessels J., et al. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens 20 (2007) 44-52
28. Phillips B.G., Narkiewicz K., Pesek C.A., et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 17 (1999) 61-66
29. Jordan W., Reinbacher A., Cohrs S., et al. Obstructive sleep apnea: plasma endothelin-1 precursor but not endothelin-1 levels are elevated and decline with nasal continuous positive airway pressure. Peptides 26 (2005) 1654-1660
30. Zamarrón-Sanz C., Ricoy-Galbaldon J., Gude-Sampedro F., et al. Plasma levels of vascular endothelial markers in obstructive sleep apnea. Arch Med Res 37 (2006) 552-555
31. Saarelainen S., Seppälä E., Laasonen K., et al. Circulating endothelin-1 in obstructive sleep apnea. Endothelium 5 (1997) 115-118
32. Grimpen F., Kanne P., Schulz E., et al. Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnea. Eur Respir J 15 (2000) 320-325
33. Rossi G.P., and Pitter G. Genetic variation in the endothelin system: do polymorphisms affect the therapeutic strategies?. Ann N Y Acad Sci 1069 (2006) 34-50
34. Ii M., Nishimura H., Iwakura A., et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation 111 (2005) 1114-1120
35. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 (1995) 1235-1241
36. Price D.T., and Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 107 (1999) 85-97
37. Davies M.J. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 82 (1996) 1-32
38. von Känel R., and Dimsdale J.E. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124 (2003) 1956-1967
39. Rångemark C., Hedner J.A., Carlson J.T., et al. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 18 (1995) 188-194
40. von Kanel R., Le D.T., Nelesen R.A., et al. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 19 (2001) 1445-1451
41. von Känel R., Loredo J.S., Ancoli-Israel S., et al. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 56 (2007) 969-976
42. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
43. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
44. Urbich C., and Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95 (2004) 343-353
45. El Solh A.A., Akinnusi M.E., Baddoura F.H., et al. Endothelial cell apoptosis in obstructive sleep apnea. A link to endothelial dysfunction. Am J Respir Crit Care Med 175 (2007) 1186-1191
46. Lavie L., Kraiczi H., Hefetz A., et al. Plasma vascular endothelial growth factor in sleep apnea syndrome. Am J Respir Crit Care Med 165 (2002) 1624-1628
47. Schulz R., Hummel C., Heinemann S., et al. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 165 (2002) 67-70
48. Peled N., Shitrit D., Bendayan D., et al. Association of elevated levels of vascular endothelial growth factor in obstructive sleep apnea syndrome with patient age rather than with obstructive sleep apnea syndrome severity. Respiration 74 (2007) 50-55
49. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., et al. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87 (2001) 805-807
50. Miyazawa-Hoshimoto S., Takahashi K., Bujo J., et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologica 46 (2003) 1483-1488
51. Valipour A., Litschauer B., Mittermayer F., et al. Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing. Respir Med 98 (2004) 1180-1186
52. McQuillan L.P., Leung G.K., Marsden P.A., et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 267 (1994) H1921-H1927
53. Liao J.K., Zulueta J.J., Yu F.S., et al. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J Clin Invest 96 (1995) 2661-2666
54. Takemoto M., Sun J., Hiroki J., et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 57-62
55. Wang P., and Zweier J.L. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem 271 (1996) 29223-29230
56. Laursen J.B., Somers M., Kurz S., et al. Endothelial regulation of vasomotion in ApoE deficient mice. Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103 (2001) 1282-1288
57. Kuzkaya N., Weissmann N., Harrison D.G., et al. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278 (2003) 22546-22554
58. Antoniades C., Shirodaria C., Warrick N., et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114 (2006) 1193-1201
59. Thomas S.R., Chen K., and Keaney Jr. J.F. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J Biol Chem 277 (2002) 6017-6024
60. Tanaka T., Nakamura H., Yodoi J., et al. Redox regulation of the signaling pathways leading to eNOS phosphorylation. Free Radic Biol Med 38 (2005) 1231-1242
61. Knepler Jr. J.L., Taher L.N., Gupta M.P., et al. Peroxynitrite causes endothelial cell monolayer barrier dysfunction. Am J Physiol Cell Physiol 281 (2001) C1064-C1075
62. Svatikova A., Wolk R., Wang H.H., et al. Circulating free nitrotyrosine in obstructive sleep apnea. Am J Physiol Regul Integr Comp Physiol 287 (2004) R284-R287
63. Tabrizi-Fard M.A., Maurer T.S., and Fung H.L. In vivo disposition of 3-nitro-l-tyrosine in rats: implications on tracking systemic peroxynitrite exposure. Drug Metab Dispos 27 (1999) 429-431
64. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci 95 (1998) 9220-9225
65. Xia Y., Tsai A.L., Berka V., et al. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273 (1998) 25804-25808
66. Kleinert H., Pautz A., Linker K., et al. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 500 (2004) 255-266
67. Xia Y., Roman L.J., Masters B.S., et al. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem 273 (1998) 22635-22639
68. Gilroy D.W., Colville-Nash P.R., Willis D., et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5 (1999) 698-701
69. Antman E.M., DeMets D., and Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 (2005) 759-770
70. Bolli R., Shinmura K., Tang X.L., et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55 (2002) 506-519
71. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
72. Dor Y., Porat R., and Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol 280 (2001) C1367-C1374
73. Marti H.H., and Risau W. Systemic hypoxia changes the organ specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci 95 (1998) 15809-15814
74. Forsythe J.A., Jiang B.H., Lyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
75. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98 (1998) 108-116
76. Winnicki M., Shamsuzzaman A., Lanfranchi P., et al. Erythropoietin and obstructive sleep apnea. Am J Hypertens 17 (2004) 783-786
77. Toffoli S., Feron O., Raes M., et al. Intermittent hypoxia changes HIF-1α phosphorylation pattern in endothelial cells: unraveling of a new PKA-dependent regulation of HIF-1α. Biochim Biophys Acta 1773 (2007) 1558-1571
78. Yuan G., Nanduri J., Bhasker C.R., et al. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 280 (2005) 4321-4328
79. Ryan S., Taylor C.T., and McNicholas W.T. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112 (2005) 2660-2667
80. Greenberg H., Ye X., Wilson D., et al. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343 (2006) 591-596
81. Williams A., and Scharf S.M. Obstructive sleep apnea, cardiovascular disease, and inflammation-is NF-kappaB the key?. Sleep Breath 11 (2007) 69-76
82. Hayakawa M., Miyashita H., Sakamoto I., et al. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 22 (2003) 3356-3366
83. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
84. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9 (2003) 1370-1376
85. Dhar-Mascareno M., Carcamo J.M., and Golde D.W. Hypoxia-reoxygenation-induced mitochondrial damage and apoptosis in human endothelial cells are inhibited by vitamin C. Free Radic Biol Med 38 (2005) 1311-1322
86. Ayas N.T., White D.P., Manson J.E., et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med 163 (2003) 205-209
87. Takase B., Akima T., Uehata A., et al. Effect of chronic stress and sleep deprivation on both flow-mediated dilation in the brachial artery and the intracellular magnesium level in humans. Clin Cardiol 27 (2004) 223-227
88. Meier-Ewert H.K., Ridker P.M., Rifai N., et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 43 (2004) 678-683
89. Vgontzas A.N., Zoumakis E., Bixler E.O., et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 89 (2004) 2119-2126
90. Irwin M., Wang M., Campomayor C.O., et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 166 (2006) 1756-1762
91. von Känel R., Dimsdale J.E., Ancoli-Israel S., et al. Poor sleep is associated with higher plasma proinflammatory cytokine interleukin-6 and procoagulant marker fibrin d-dimer in older caregivers of people with Alzheimer's disease. J Am Geriatr Soc 54 (2006) 431-437
92. Mausbach B.T., Ancoli-Israel S., von Känel R., et al. Sleep disturbance, norepinephrine, and d-dimer are all related in elderly caregivers of people with Alzheimer disease. Sleep 29 (2006) 1347-1352
93. von Känel R., Loredo J.S., Ancoli-Israel S., et al. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 131 (2007) 733-739
94. Sullivan C.E., Issa F.G., Berthon-Jones M., et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1 (1981) 862-865
95. Lattimore J.L., Wilcox I., Skilton M., et al. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 61 (2006) 491-495
96. Imadojemu V.A., Gleeson K., Quraishi S.A., et al. Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure. Am J Respir Crit Care Med 165 (2002) 950-953
97. Becker H.F., Jerrentrup A., Ploch T., et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107 (2003) 68-73
98. Pepperell J.C., Ramdassingh-Dow S., Crosthwaite N., et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 359 (2002) 204-210
99. Chin K., Nakamura T., Shimizu K., et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 109 (2000) 562-567
100. Barcelo A., Barbe F., de la Pena M., et al. Antioxidant status in patients with sleep apnea and impact of continuous positive airway pressure treatment. Eur Respir J 27 (2006) 756-760
101. Phillips C.L., Yang Q., Williams A., et al. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnea. J Sleep Res 16 (2007) 217-225
102. Robinson G.V., Smith D.M., Langford B.A., et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 27 (2006) 1229-1235
103. Patruno V., Aiolfi S., Costantino G., et al. Fixed and autoadjusting continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep apnea. Chest 131 (2007) 1393-1399
104. Farré R., Montserrat J.M., Rigau J., et al. Response of automatic continuous positive airway pressure devices to different sleep breathing patterns: a bench study. Am J Respir Crit Care Med 166 (2002) 469-473
105. Kheirandish-Gozal L., Capdevila O.S., Tauman R., et al. Plasma C-reactive protein in nonobese children with obstructive sleep apnea before and after adenotonsillectomy. J Clin Sleep Med 2 (2006) 301-304
106. Gozal D., Serpero L.D., Sans Capdevila O., et al. Systemic inflammation in non-obese children with obstructive sleep apnea. Sleep Med 9 (2008) 254-259
107. Gozal D., Kheirandish-Gozal L., Serpero L.D., et al. Obstructive sleep apnea and endothelial function in school-aged nonobese children: effect of adenotonsillectomy. Circulation 116 (2007) 2307-2314
108. Yilmaz M.D., Onrat E., Altuntas A., et al. The effects of tonsillectomy and adenoidectomy on pulmonary arterial pressure in children. Am J Otolaryngol 26 (2005) 18-21
109. Tezer M.S., Karanfil A., and Aktas D. Association between adenoidal-nasopharyngeal ratio and right ventricular diastolic functions in children with adenoid hypertrophy causing upper airway obstruction. Int J Pediatr Otorhinolaryngol 69 (2005) 1169-1173
110. Kinoshita H., Shibano A., Sakoda T., et al. Uvulopalatopharyngoplasty decreases levels of C-reactive protein in patients with obstructive sleep apnea syndrome. Am Heart J 152 (2006) 692.e1-692.e5
111. Kataoka T., Enomoto F., Kim R., et al. The effect of surgical treatment of obstructive sleep apnea syndrome on the plasma TNF-alpha levels. Tohuku J Exp Med 204 (2004) 267-272
112. Schwab R.J., Pasirstein M., Pierson R., et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 168 (2003) 522-530
113. Ng A.T., Qian J., and Cistulli P.A. Oropharyngeal collapse predicts treatment response with oral appliance therapy in obstructive sleep apnea. Sleep 29 (2006) 666-671
114. Gotsopoulos H., Kelly J.J., and Cistulli P.A. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 27 (2004) 934-941
115. Itzhaki S., Dorchin H., Clark G., et al. The effects of 1-year treatment with a Herbst mandibular advancement splint on obstructive sleep apnea, oxidative stress, and endothelial function. Chest 131 (2007) 740-749
116. Weaver T.E., Kribbs N.B., Pack A.I., et al. Night-to-night variability in CPAP use over the first three months of treatment. Sleep 20 (1997) 278-283
117. Marklund M. Predictors of long-term orthodontic side effects from mandibular advancement devices in patients with snoring and obstructive sleep apnea. Am J Orthod Dentofac Orthop 129 (2006) 214-221
118. Sundaram S., Bridgman S.A., Lim J., et al. Surgery for obstructive sleep apnea. Cochrane Database Syst Rev (2005) CD001004
119. El Solh A.A., Saliba R., Bosinski T., et al. Allopurinol improves endothelial function in sleep apnea: a randomized controlled study. Eur Respir J 27 (2006) 997-1002
120. Grebe M., Eisele H.J., Weissmann N., et al. Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 173 (2006) 897-901
121. Raitakari O.T., Adams M.R., McCredie R.J., et al. Oral vitamin C and endothelial function in smokers: short-term improvement, but no sustained beneficial effect. J Am Coll Cardiol 35 (2000) 1616-1621